Sign in
Immunogenicity and Safety of Beta-Adjuvanted Recombinant Booster Vaccine
Journal article   Open access  Peer reviewed

Immunogenicity and Safety of Beta-Adjuvanted Recombinant Booster Vaccine

Odile Launay, Marine Cachanado, Liem B. Luong Nguyen, Laetitia Ninove, Marie Lachâtre, Inès Ben Ghezala, Marc Bardou, Catherine Schmidt-Mutter, Karine Lacombe, Fabrice Laine, …
The New England journal of medicine, Vol.387(4), pp.374-376
28/07/2022
PMID: 35767474

Abstract

Coronavirus Infectious Disease Vaccines Viral Infections
In a small trial of boost immunization with the mRNA vaccine originally received or with heterologous boosting with spike proteins from the original strain or the beta variant, the beta-adjuvanted booster resulted in the highest titers of antibody and activated T cells 2 weeks later.
url
https://doi.org/10.1056/NEJMc2206711View
Published (Version of record) Open

Details